Encapsulated galanin-producing cells attenuate focal epileptic seizures in the hippocampus.

Research output: Contribution to journalArticle

Abstract

Encapsulated cell biodelivery (ECB) is a relatively safe approach, since the devices can be removed in the event of adverse effects. The main objectives of the present study were to evaluate whether ECB could be a viable alternative of cell therapy for epilepsy. We therefore developed a human cell line producing galanin, a neuropeptide that has been shown to exert inhibitory effects on seizures, most likely acting via decreasing glutamate release from excitatory synapses. To explore whether ECB of genetically modified galanin-producing human cell line could provide seizure-suppressant effects, and test possible translational prospect for clinical application, we implanted ECB devices bilaterally into the hippocampus of rats subjected to rapid kindling, a model for recurrent temporal lobe seizures.

Details

Authors
  • Litsa Nikitidou
  • Malene Torp
  • Lone Fjord-Larsen
  • Philip Kusk
  • Lars U Wahlberg
  • Merab Kokaia
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurology
Original languageEnglish
Pages (from-to)167-174
JournalEpilepsia
Volume55
Issue number1
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes